Director RSUs vest into 21,000 Precision BioSciences shares

PRECISION BIOSCIENCES INC director Shari Lisa Pire reported a compensation-related share acquisition.

Rhea-AI Filing Summary

PRECISION BIOSCIENCES INC director Shari Lisa Pire reported a compensation-related share acquisition. On May 20, 2026, 21,000 Restricted Stock Units vested and were settled into 21,000 shares of Common Stock. No sale was reported, and she now directly holds 35,028 Common Shares.

The RSUs were originally granted on June 3, 2025 and were scheduled to vest on the earlier of June 3, 2026 or the day before the next annual stockholder meeting, subject to her continued service. Each RSU represented the right to receive one share of Common Stock upon vesting.

Insider Trade Summary

21,000 shares exercised/converted

Exercise 2 txns

Insider Pire Shari Lisa

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	21,000	$0.00	$0.00
Exercise	Common Stock	21,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 35,028 shares (Direct)

Footnotes (3)

1. F1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

RSUs vested: 21,000 units Shares received from vesting: 21,000 shares Shares held after transaction: 35,028 shares +2 more

5 metrics

RSUs vested 21,000 units Restricted Stock Units converting to Common Stock on May 20, 2026

Shares received from vesting 21,000 shares Common Stock acquired upon RSU vesting

Shares held after transaction 35,028 shares Director’s direct Common Stock holdings following RSU conversion

RSU grant date June 3, 2025 Grant date for the Restricted Stock Units that later vested

RSU vesting triggers Earlier of June 3, 2026 or pre-annual meeting Vesting schedule subject to continued service

Key Terms

Restricted Stock Units ("RSUs"), contingent right, Issuer's Common Stock, vesting date

4 terms

Restricted Stock Units ("RSUs") financial

"Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Issuer's Common Stock financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vesting date financial

"subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Precision BioSciences (DTIL) report for Shari Lisa Pire?

Precision BioSciences director Shari Lisa Pire reported the vesting of 21,000 Restricted Stock Units into 21,000 shares of Common Stock. This was a compensation-related equity award, with no open-market sale disclosed in this Form 4 filing.

How many Precision BioSciences (DTIL) shares does Shari Lisa Pire hold after this Form 4?

After the RSU vesting, Shari Lisa Pire directly holds 35,028 shares of Precision BioSciences Common Stock. This total reflects the addition of 21,000 shares received upon vesting of her Restricted Stock Units on May 20, 2026.

Were any Precision BioSciences (DTIL) shares sold in this Form 4 transaction?

No sale was reported in this Form 4. The filing shows an exercise or conversion of 21,000 Restricted Stock Units into 21,000 Common Shares, with no separate disposition or open-market sale transaction disclosed for these shares.

What are the terms of Shari Lisa Pire’s RSU grant at Precision BioSciences (DTIL)?

The RSUs were granted on June 3, 2025 and vested on the earlier of June 3, 2026 or the day before the next annual stockholder meeting. Vesting was subject to her continued service, with each RSU delivering one Common Share upon vesting.

What does the RSU vesting mean for Precision BioSciences (DTIL) shareholders?

The RSU vesting increased outstanding Common Shares held by director Shari Lisa Pire by 21,000. This reflects stock-based compensation rather than a market purchase or sale, and simply converts an existing award into actual shares she now directly owns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 07:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pire Shari Lisa

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW STREET, SUITE A-100

(Street)

DURHAM NORTH CAROLINA 27701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		M		21,000(1)	A	(2)	35,028	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	05/20/2026		M			21,000	(3)	(3)	Common Stock	21,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Dario Scimeca, Attorney-in-Fact for Shari Lisa Pire	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)